Clearpoint Neuro (CLPT) Investor presentation summary

Growth strategy and targets

• Target 20% share of a stated $1.0B existing global market, generating $200M in annual revenue and reaching cash breakeven and profitability along the way.

• A five-pillar strategy adds commercial drug delivery, with a stated goal of $500M in revenue; the plan includes capacity for 5,000 cell and gene therapy procedures.

• The cell and gene therapy strategy targets capacity for 20,000 annual procedures and an additional $300M in annual revenue; the presentation describes a potential new $10B market.

Financial position and scale

• 2025 revenue was $37.0M; 2026 revenue is estimated at $48.0M–$50.0M.

• Gross margin was 61% on an unaudited trailing-12-month basis ended September 30, 2026; cash and cash equivalents were $46.2M as of and for the quarter ended September 30, 2026.

• Installed base exceeded 175 active global centers; more than 160 employees worldwide were focused on neuro, with 130+ issued and licensed patents.

Platform and commercial opportunity

• The platform combines navigation, modeling, delivery devices, infusion monitoring software, clinical support, and preclinical services; it has been used in more than 10,000 procedures and has regulatory approvals in 34 countries.

• More than 60 active pharma partners and 25+ active clinical trials span 15+ neuro-focused indications; 10+ programs have been accepted for FDA expedited review.

• In 2024, the first FDA-approved gene therapy for AADC deficiency, Kebilidi, was labeled as a combination product with the SmartFlow Neuro Cannula, the only FDA-authorized device indicated to administer it.